Notably, the present study for the first time directly correlates the efficacy of herbal compound with TLR4/MAPK pathway modulation, providing experimental evidence for the advantages of JZD multi-target intervention in SLE. The gene discussed is TLR4; the disease is systemic lupus erythematosus.